trial · primary record
JADE101
IgA Nephropathy (IgAN)
| Phase | Phase 3 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 480 |
| Primary completion | 2030-09 |
| Primary endpoint | To evaluate the effect of JADE101 on Urine Protein Creatinine Ratio (UPCR) in participants with IgA nephropathy |
| Registry ID | NCT07902817 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-29T14:32:08.445Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07902817
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.